Tissue | Expression Dynamics | Abbreviation |
Breast | | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
GC | | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00069596 | Breast | IDC | humoral immune response | 40/1434 | 317/18723 | 1.25e-03 | 1.33e-02 | 40 |
GO:00512515 | Breast | IDC | positive regulation of lymphocyte activation | 43/1434 | 362/18723 | 2.72e-03 | 2.41e-02 | 43 |
GO:00022532 | Breast | IDC | activation of immune response | 43/1434 | 375/18723 | 5.16e-03 | 3.84e-02 | 43 |
GO:00026966 | Breast | IDC | positive regulation of leukocyte activation | 46/1434 | 409/18723 | 5.60e-03 | 4.07e-02 | 46 |
GO:005125111 | Breast | DCIS | positive regulation of lymphocyte activation | 42/1390 | 362/18723 | 2.65e-03 | 2.35e-02 | 42 |
GO:000225311 | Breast | DCIS | activation of immune response | 43/1390 | 375/18723 | 2.96e-03 | 2.54e-02 | 43 |
GO:000695911 | Breast | DCIS | humoral immune response | 37/1390 | 317/18723 | 4.16e-03 | 3.29e-02 | 37 |
GO:00027644 | Cervix | CC | immune response-regulating signaling pathway | 97/2311 | 468/18723 | 1.49e-07 | 7.07e-06 | 97 |
GO:00022533 | Cervix | CC | activation of immune response | 72/2311 | 375/18723 | 8.26e-05 | 1.11e-03 | 72 |
GO:0002768 | Cervix | CC | immune response-regulating cell surface receptor signaling pathway | 59/2311 | 315/18723 | 6.64e-04 | 6.11e-03 | 59 |
GO:00026967 | Cervix | CC | positive regulation of leukocyte activation | 72/2311 | 409/18723 | 1.13e-03 | 9.31e-03 | 72 |
GO:00512516 | Cervix | CC | positive regulation of lymphocyte activation | 65/2311 | 362/18723 | 1.15e-03 | 9.39e-03 | 65 |
GO:00508676 | Cervix | CC | positive regulation of cell activation | 73/2311 | 420/18723 | 1.50e-03 | 1.16e-02 | 73 |
GO:00024603 | Cervix | CC | adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains | 62/2311 | 356/18723 | 3.09e-03 | 2.03e-02 | 62 |
GO:0002443 | Cervix | CC | leukocyte mediated immunity | 73/2311 | 440/18723 | 5.01e-03 | 2.98e-02 | 73 |
GO:0006909 | Cervix | CC | phagocytosis | 53/2311 | 308/18723 | 7.49e-03 | 4.01e-02 | 53 |
GO:00069597 | Cervix | CC | humoral immune response | 54/2311 | 317/18723 | 8.57e-03 | 4.42e-02 | 54 |
GO:00103243 | Cervix | CC | membrane invagination | 28/2311 | 144/18723 | 9.50e-03 | 4.72e-02 | 28 |
GO:000695912 | Cervix | HSIL_HPV | humoral immune response | 39/737 | 317/18723 | 2.88e-10 | 7.02e-08 | 39 |
GO:000269611 | Cervix | HSIL_HPV | positive regulation of leukocyte activation | 44/737 | 409/18723 | 1.58e-09 | 3.04e-07 | 44 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
IGLC2 | SNV | Missense_Mutation | novel | c.22N>T | p.Ser8Leu | p.S8L | | IG_C_gene | deleterious_low_confidence(0) | benign(0.023) | TCGA-A8-A06R-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | CR |
IGLC2 | SNV | Missense_Mutation | rs371508809 | c.151N>T | p.Ala51Val | p.A51V | | IG_C_gene | deleterious_low_confidence(0) | benign(0) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
IGLC2 | SNV | Missense_Mutation | novel | c.130N>A | p.Ala44Glu | p.A44E | | IG_C_gene | deleterious_low_confidence(0) | benign(0.272) | TCGA-C5-A902-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
IGLC2 | SNV | Missense_Mutation | rs759610154 | c.280N>T | p.Ser94Ile | p.S94I | | IG_C_gene | deleterious_low_confidence(0) | benign(0.067) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
IGLC2 | SNV | Missense_Mutation | novel | c.12N>A | p.Ala5Thr | p.A5T | | IG_C_gene | deleterious_low_confidence(0) | benign(0.027) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
IGLC2 | SNV | Missense_Mutation | novel | c.226N>T | p.Pro76Leu | p.P76L | | IG_C_gene | deleterious_low_confidence(0) | possibly_damaging(0.494) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
IGLC2 | SNV | Missense_Mutation | novel | c.177N>G | p.Lys60Glu | p.K60E | | IG_C_gene | deleterious_low_confidence(0) | probably_damaging(0.978) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
IGLC2 | SNV | Missense_Mutation | rs755014029 | c.223N>T | p.Thr75Met | p.T75M | | IG_C_gene | deleterious_low_confidence(0) | benign(0.349) | TCGA-EO-A3AZ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
IGLC2 | SNV | Missense_Mutation | novel | c.22C>T | p.Ser8Leu | p.S8L | | IG_C_gene | deleterious_low_confidence(0) | benign(0.023) | TCGA-EY-A549-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
IGLC2 | SNV | Missense_Mutation | novel | c.136N>A | p.Ser46Asn | p.S46N | | IG_C_gene | deleterious_low_confidence(0) | benign(0.001) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |